The study will test the antibody-drug conjugate in combination with Keytruda in patients with HER2-overexpressing metastatic non-small cell lung cancer.

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced a cost-cutting plan ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Dow Jones Top Company Headlines at 9 AM ET: Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings | Novo ... Eli Lilly reported higher profit and raised its outlook on surging demand for its ...

Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise. The pharmaceutical company reported net income of $5.79 ...

Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of ...

Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling ...

Merck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...

Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy ...